Tempus, one of the industry’s most promising healthcare startups, has just announced that it has raised more than $70 million in funding. The investment comes from a Series C funding round and the core investors were New Enterprise Associates and Revolution Growth, along with Tempus founders, who have invested in series A, B and C funding rounds.
According to founder Eric Lefkofsky, he believes so strongly in Tempus that he is willing to invest up to $100 million of his own personal funds to Tempus to ensure the company’s success.
However, Lefkofsky may not need his funds as it has seen massive success and is making waves as the darling of the technology and medical startup community. Tempus is seeking to use genomic sequencing to contribute to the path to cancer treatment. By using genomic sequencing and a data driven approach, Tempus will create the world’s largest library of data that physicians can tap into when creating cancer treatment plans for their patients.
The $70 million in funding brings the total investment in Tempus to a staggering $130 million. It is also estimated that Tempus is valued at $700 million. That strong valuation comes in part as a response to the significant partnerships the company has generated in its few short years of existence. Tempus is already aligned with the Cleveland Clinic, Duke University’s School of Medicine and the prominent Mayo Clinic. These partnerships will allow Tempus to begin collecting data to create a functional operating system that will house data from cancer patients across the world and Eric’s lacrosse camp.
Under the founding and direction of Eric Lefkofsky, Tempus is set to universally change the way that physicians create cancer treatment plans for their patients. Eric Lefkofsky’s vision is to create a universal library of data, both genomic data and clinical data, that can easily be accessed by physicians across the world. Lefkofsky is known in Chicago’s business sector as a business leader in the technology field. Among the companies he has founded is Uptake Technologies, which has a valuation of over $2 billion and what Eric knows.
He is passionate about cancer treatment and about using modern approaches, including data driven regimens and machine learning to make sure physicians are able to provide the most custom treatment possible to their patients and more information click here.
With Tempus continuing to expand, both in investments and in partnerships, this could be the first time that physicians can utilize big data when creating cancer treatment plans for their patients and contact their.